The HIV epidemic continues to be a significant global health challenge with more than 38 million people living with HIV. Around the world, advocates, researchers and other inspiring individuals are working on the frontlines to better the lives of people living with and impacted by HIV.
We’re proud to have played a role in bringing forward nine medicines for people living with HIV, redefining what it means to live with this virus and advancing our mission to make HIV history.
Our vision is a world without HIV. That’s why we are committed to bringing forward new prevention options that are needed to help stop the global HIV epidemic in its tracks.
Our commitment is unwavering, and we remain dedicated to ushering in new advancements in prevention and therapy for the HIV community. Together, we’re helping to build a world without HIV and we won't stop until we make HIV history.
For decades, the Johnson & Johnson Foundation has partnered with local organizations to equip health workers with specialized training, education and novel technologies to support people living with HIV and help prevent future infections.
The late Dr. Paul Janssen and the Janssen Research Foundation begin a new partnership with the Rega Institute to screen anti-HIV compounds.
The Janssen Research Foundation moves its first compound for the treatment of HIV into clinical development.
The Janssen Research Foundation signs a five-year agreement with Tibotec and founder Dr. Rudi Pauwels to continue the quest for better HIV inhibitors. A year later, Dr. Paul Stoffels co-founds Virco with Dr. Pauwels.
The company becomes part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and begins late-stage trials on a breakthrough medicine.
Janssen’s next-generation protease inhibitor is granted accelerated approval by the U.S. Food and Drug Administration (FDA) prior to finishing Phase III trials.
Janssen’s next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved for use in combination with other antiretroviral medicines for patients with established resistance to other drugs.
Janssen’s third HIV medication, a next-generation NNRTI, is approved by the U.S. FDA. The company partners with Gilead and then ViiV Healthcare to create a single-tablet, multi-drug HIV regimen based on this NNRTI.
Janssen announces it will donate two of its HIV medicines, including child-friendly formulations, free of charge to eligible countries in sub-Saharan Africa.
Johnson & Johnson and its partners launch the New Horizons Collaborative in sub-Saharan Africa to improve access and scale-up of pediatric HIV treatment. The program is later expanded to 11 total countries.
Janssen and Gilead collaborate in the clinical development of a once daily, single-tablet regimen containing Janssen’s protease inhibitor for the treatment of people living with HIV.
The Phase 2b efficacy trial of Janssen’s investigational preventive HIV vaccine regimen begins. The study goes on to enroll over 2,600 young women in Malawi, Mozambique, South Africa, Zambia and Zimbabwe.
A new treatment comprised of medicines developed by ViiV Healthcare and Janssen is approved as a once-daily regimen, offering a new and simplified option for people living with HIV.
Johnson & Johnson, joined by the United Nations Population Fund, launch the initiative to promote empowerment and HIV prevention education among adolescent girls and young women in sub-Saharan Africa.
Johnson & Johnson joins Sir Elton John; Prince Harry, Duke of Sussex; and other global partners to support the launch of the MenStar Coalition to expand diagnosis and treatment of HIV in men.
Johnson & Johnson’s once-daily single-tablet regimen is approved by the U.S. FDA, offering a new treatment option for adults living with HIV.
Johnson & Johnson announces four-year commitment, focused on developing new innovations and accelerating the delivery of existing and new tools to combat both epidemics.
The Phase 3 trial launches to test the efficacy of Janssen’s investigational preventive HIV vaccine regimen among transgender individuals and cisgender men who have sex with men in the Americas and Europe.
The world’s first long-acting, discreet HIV prevention option for women, developed by the International Partnership for Microbicides under an exclusive license from Janssen, is recommended for use by the WHO.
The European Commission authorizes the world’s first long-acting injectable treatment regimen for HIV, which was co-developed by Johnson & Johnson and ViiV Healthcare.
Positive 96-week data presented by Janssen on the long-acting, injectable treatment regimen demonstrates the efficacy the regimen over a six-times-per-year dosing schedule.
U.S. FDA approves every-two-months dosing schedule for long-acting injectable HIV treatment regimen co-developed by Johnson & Johnson & ViiV Healthcare
U.S. FDA gives adults with HIV the option to begin taking Johnson & Johnson and ViiV Healthcare’s long-acting injectable HIV treatment regimen without oral lead-in period
South African Health Products and Regulatory Authority (SAHPRA) approves once-monthly dapivirine vaginal ring, developed by International Partnership for Microbicides under license from Janssen.
U.S. FDA approves first long-acting injectable HIV treatment regimen, co-developed by Johnson & Johnson and ViiV Healthcare, for eligible adolescents.